Literature DB >> 16109665

Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers.

Sara Islam1, Linda Antonsson, Johan Westin, Martin Lagging.   

Abstract

OBJECTIVE: Assessment of liver histology is pivotal in prognostication and decision-making regarding therapeutic intervention in patients with chronic hepatitis C virus (HCV). Being an invasive procedure, the liver biopsy is associated with complications, and a non-invasive alternative would be preferable.
MATERIAL AND METHODS: Sera samples from 179 patients with chronic HCV infection collected at the time of liver biopsy were analyzed using routinely available biochemical markers of liver disease, and liver histology was evaluated using the Ishak protocol. The relationship between the serum biochemical markers and cirrhosis (Ishak stage > or = 5) as well as bridging fibrosis (Ishak stage > or = 3) was examined.
RESULTS: A strong association was found in the multivariate logistic regression analysis between fibrosis stage and aspartate aminotransferase (AST), platelet count and prothrombin-INR (international normalized ratio). An index (the Göteborg University Cirrhosis Index (GUCI)) was calculated using these variables: normalized ASTxprothrombin-INRx100/platelet count (x 10(9)/l). Using a cut-off value of 1.0, the sensitivity was 80% and the specificity 78% for diagnosis of cirrhosis, and the negative predictive values (NPV) and positive predictive values (PPV) were 97% and 31%, respectively. The GUCI score proved slightly superior for sensitivity, specificity, NPV, PPV, and the area under the receiver operating characteristic (ROC) curve for prediction of cirrhosis and bridging fibrosis compared with the AST to platelet ratio index (APRI), which has been reported as a predictor of significant fibrosis and cirrhosis.
CONCLUSION: An index using routinely available biochemical markers can with a high degree of accuracy discriminate patients with from those without hepatitis C-related cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109665     DOI: 10.1080/00365520510015674

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  34 in total

Review 1.  Liver elastography, comments on EFSUMB elastography guidelines 2013.

Authors:  Xin-Wu Cui; Mireen Friedrich-Rust; Chiara De Molo; Andre Ignee; Dagmar Schreiber-Dietrich; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

2.  Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

Authors:  Giada Sebastiani; Alessandro Vario; Maria Guido; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

3.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

4.  A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo.

Authors:  Tao Guo; Zu-Long Liu; Qiang Zhao; Zhi-Min Zhao; Cheng-Hai Liu
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

5.  Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection.

Authors:  Shawky Abdelhamid Fouad; Serag Esmat; Dalia Omran; Laila Rashid; Mohamed H Kobaisi
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

6.  Non-invasive assessment of liver fibrosis in chronic hepatitis C.

Authors:  Laurent Castera
Journal:  Hepatol Int       Date:  2011-01-20       Impact factor: 6.047

7.  Prognostic value of non-invasive fibrosis indices post-curative resection in hepatitis-B-associated hepatocellular carcinoma patients.

Authors:  Ting-Ting Zhang; Si-Si Ye; Jun Liang; Li Bai
Journal:  Exp Biol Med (Maywood)       Date:  2020-03-29

Review 8.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

9.  Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma.

Authors:  Su Jong Yu; Jeong Hoon Lee; Goh Eun Chung; Chang Hoon Lee; Eun Ju Cho; Eun Sun Jang; Min Sun Kwak; Yoon Jun Kim; Jung Hwan Yoon; Ja June Jang; Hyo Suk Lee
Journal:  Korean J Hepatol       Date:  2010-12

10.  Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.

Authors:  G Usluer; N Erben; N Aykin; O Dagli; O Aydogdu; S Barut; F Cevik; B Ormen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.